| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aberrant spliceosome kinetics and structural variations drive the production of soluble PD-L1 mRNA in various cancer and immune cell types
|
Papamichos, S.I.
|
|
|
|
S11 |
p. xi24
|
artikel
|
| 2 |
Abundance of Treg cells in oral cancer patients and effects of their inhibition on growth of cancer cells
|
Aggarwal, S.
|
|
|
|
S11 |
p. xi26
|
artikel
|
| 3 |
A clinical insight into therapeutic sequence in advanced melanoma
|
Vera-Aguilera, J.
|
|
|
|
S11 |
p. xi23-xi24
|
artikel
|
| 4 |
A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy
|
Heesen, L.
|
|
|
|
S11 |
p. xi14-xi15
|
artikel
|
| 5 |
Antitumor effects of EGF-pathway immunization in NSCLC
|
Codony-Servat, J.
|
|
|
|
S11 |
p. xi17-xi18
|
artikel
|
| 6 |
A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma
|
Patel, S.P.
|
|
|
|
S11 |
p. xi30
|
artikel
|
| 7 |
A retrospective analysis of response to checkpoint inhibitors and its correlation to both PD-L1 score and tumor mutation burden in patients with solid tumor malignancies
|
Kazmi, S.M.
|
|
|
|
S11 |
p. xi10
|
artikel
|
| 8 |
A retrospective analysis to evaluate prevalence and correlation between PD-L1 score and tumor mutational burden (TMB) levels in patients with solid tumor malignancies
|
Kazmi, S.M.
|
|
|
|
S11 |
p. xi10-xi11
|
artikel
|
| 9 |
Arming oncolytic adenovirus with FAP-targeting bispecific T-cell engager to improve antitumor efficacy
|
de Sostoa Pomés, J.
|
|
|
|
S11 |
p. xi18
|
artikel
|
| 10 |
Association of p53-autoantibodies with TP53 somatic mutational profile detected by next generation sequencing in advanced high-grade ovarian cancer
|
Garziera, M.
|
|
|
|
S11 |
p. xi12
|
artikel
|
| 11 |
Association of PDL1 expression with TP53, KRAS mutation, and microsatellite instability in Indonesian patients with colorectal cancer
|
Putra, T.P.
|
|
|
|
S11 |
p. xi11
|
artikel
|
| 12 |
author index
|
|
|
|
|
S11 |
p. xi89-xi98
|
artikel
|
| 13 |
author index
|
|
|
|
|
S11 |
p. xi93-xi103
|
artikel
|
| 14 |
Biology of plasmacytoid dendritic cells in head and neck cancer
|
Koucký, V.
|
|
|
|
S11 |
p. xi25-xi26
|
artikel
|
| 15 |
Chemokine receptor 2 (CCR2) antagonism with a small molecule enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumours: Reducing tumor size and increasing long term survival
|
Campbell, J.
|
|
|
|
S11 |
p. xi20
|
artikel
|
| 16 |
Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
|
Galli, G.
|
|
|
|
S11 |
p. xi8
|
artikel
|
| 17 |
Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress
|
Kjeldsen, J.W.
|
|
|
|
S11 |
p. xi27-xi28
|
artikel
|
| 18 |
Combined immunotherapy encompassing intratumoral polyICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
|
Rodríguez-Ruiz, M.E.
|
|
|
|
S11 |
p. xi14
|
artikel
|
| 19 |
Deciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study
|
Joshi, K.
|
|
|
|
S11 |
p. xi2
|
artikel
|
| 20 |
Delivering complete responses against solid tumors by checkpoint blockade enabled with tumor necrosis factor alpha and interleukin-2 armed adenoviruses
|
Cervera-Carrascon, V.
|
|
|
|
S11 |
p. xi15
|
artikel
|
| 21 |
Development of circulating anti-drug antibodies associate with shortened survival in patients with metastatic malignant melanoma treated with ipilimumab
|
Kverneland, A.
|
|
|
|
S11 |
p. xi21
|
artikel
|
| 22 |
Differential expression of PD-L1, MALAT1 and XIST in tumors and lymph nodes of TNBC and IDC patients and their regulation by miR-182
|
Samir, A.
|
|
|
|
S11 |
p. xi12
|
artikel
|
| 23 |
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC
|
Mazzaschi, G.
|
|
|
|
S11 |
p. xi9
|
artikel
|
| 24 |
Down-regulated miR-486-5p acts as a tumor suppressor in breast cancer patients by targeting the metastatic mediator ICAM-1
|
Abdallah, R.
|
|
|
|
S11 |
p. xi22
|
artikel
|
| 25 |
Drug Index
|
|
|
|
|
S11 |
p. xi32
|
artikel
|
| 26 |
Durable remissions associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center
|
Smit, T.
|
|
|
|
S11 |
p. xi6
|
artikel
|
| 27 |
Editorial Board
|
|
|
|
|
S11 |
p. iii-iv
|
artikel
|
| 28 |
Editorial Board
|
|
|
|
|
S11 |
p. ii-iii
|
artikel
|
| 29 |
Effect of ciclopirox olamine in immunotherapy effect by stimulating immunogenic cell death in pancreatic cancer
|
Mihailidou, C.
|
|
|
|
S11 |
p. xi21
|
artikel
|
| 30 |
Efficacy of a multipeptide bcr-abl p210 protein derived vaccine in chronic myeloid leukemia with 5-year follow up
|
Osfouri, E.
|
|
|
|
S11 |
p. xi15
|
artikel
|
| 31 |
Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial
|
Naing, A.
|
|
|
|
S11 |
p. xi1
|
artikel
|
| 32 |
Engineering T-cells for adoptive cell therapy to overcome TGF-β-mediated immunosuppression in the tumour microenvironment
|
Catchpole, I.
|
|
|
|
S11 |
p. xi27
|
artikel
|
| 33 |
Evaluating renal cell carcinoma treatment options using real world data: Findings from an oncology survey across seven countries
|
Mpima, S.
|
|
|
|
S11 |
p. xi6
|
artikel
|
| 34 |
Evaluation the effect of Brucella abortus RB51 lipopolysaccharide as an adjuvant on the efficiency of HPV-16 L1 and HPV-16 E7 DNA vaccines in C57BL/6 mice
|
Soleimanjahi, H.
|
|
|
|
S11 |
p. xi18
|
artikel
|
| 35 |
Expansion of tumor specific tumor-infiltrating lymphocytes (TIL) from sarcoma and the potential benefit of anti-CD137 stimulation: A prerequisite for adoptive cell transfer (ACT) immunotherapy
|
Nielsen, M.
|
|
|
|
S11 |
p. xi4
|
artikel
|
| 36 |
Experience of immune-related adverse events associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center
|
Rapoport, B.L.
|
|
|
|
S11 |
p. xi7
|
artikel
|
| 37 |
Expression pattern of immune checkpoints programmed death (PD-1) and programmed death-ligand (PD-L1) in retinoblastoma and its prognostic significance
|
Singh, L.
|
|
|
|
S11 |
p. xi11
|
artikel
|
| 38 |
Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program
|
Rapoport, B.L.
|
|
|
|
S11 |
p. xi6
|
artikel
|
| 39 |
Extracellular vesicle-internalizing receptors (EVIRs) for dendritic cell-based tumor vaccines
|
Squadrito, M.L.
|
|
|
|
S11 |
p. xi15
|
artikel
|
| 40 |
Flowcytometric expression of LAIR-1 inhibitory immune-receptor in pediatric acute lymphoblastic leukemia cases does not correlate with standard risk factors and minimal residual disease
|
Bhatia, P.
|
|
|
|
S11 |
p. xi26
|
artikel
|
| 41 |
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI)
|
Cleary, J.
|
|
|
|
S11 |
p. xi14-xi23
|
artikel
|
| 42 |
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI)
|
Cleary, J.
|
|
|
|
S11 |
p. xi24-xi32
|
artikel
|
| 43 |
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI)
|
Cleary, J.
|
|
|
|
S11 |
p. xi33-xi40
|
artikel
|
| 44 |
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI)
|
Cleary, J.
|
|
|
|
S11 |
p. xi41-xi50
|
artikel
|
| 45 |
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI)
|
Cleary, J.
|
|
|
|
S11 |
p. xi51-xi59
|
artikel
|
| 46 |
Gastric cancer stem-like cells, the balance operator of Th17 and Treg
|
Rezalotfi, A.
|
|
|
|
S11 |
p. xi26-xi27
|
artikel
|
| 47 |
Generation and characterization of cord blood derived T cells redirected with a TCR targeting E7/HLA-DR4 complex
|
Marton, C.
|
|
|
|
S11 |
p. xi19-xi20
|
artikel
|
| 48 |
Health-related quality of life (HRQoL) in patients (Pts) with Merkel cell carcinoma (MCC) receiving avelumab
|
Bharmal, M.
|
|
|
|
S11 |
p. xi23
|
artikel
|
| 49 |
Helicobacter pylori CagA expression is closely associated with tumor PD-L1 expression and the better prognosis of gastric cancer patients
|
Kuo, S-H
|
|
|
|
S11 |
p. xi10
|
artikel
|
| 50 |
Homology between cancer and viral epitopes as criteria to design improved cancer vaccines
|
Capasso, C.
|
|
|
|
S11 |
p. xi18
|
artikel
|
| 51 |
Identification of subsets of tumor infiltrating lymphocytes in primary brain tumors using multi-color panel flow cytometry
|
Ben-Horin, I.
|
|
|
|
S11 |
p. xi25
|
artikel
|
| 52 |
IMA950 multipeptide vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients
|
Dutoit, V.
|
|
|
|
S11 |
p. xi3-xi4
|
artikel
|
| 53 |
Immune checkpoint vaccines and radiation combination strategy
|
Lan, K-H
|
|
|
|
S11 |
p. xi16
|
artikel
|
| 54 |
Immune-mediated cystatin A expression in patients with pancreatic ductal adenocarcinoma
|
Komura, T.
|
|
|
|
S11 |
p. xi21-xi22
|
artikel
|
| 55 |
Immunomonitoring of patients treated with personalized dendritic cell-based vaccine
|
Fedorova, L.
|
|
|
|
S11 |
p. xi17
|
artikel
|
| 56 |
Immunotherapy enhanced by geroprotection: Hormone-resistant prostate cancer
|
Lasalvia-Prisco, E.M.
|
|
|
|
S11 |
p. xi22-xi23
|
artikel
|
| 57 |
Impairment of membrane TNFα expression reduces cytotoxic activity of dendritic cells against autologous tumor cells in high-grade glioma patients
|
Tyrinova, T.
|
|
|
|
S11 |
p. xi25
|
artikel
|
| 58 |
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study
|
Bersanelli, M.
|
|
|
|
S11 |
p. xi17
|
artikel
|
| 59 |
INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer
|
Csiki, I.
|
|
|
|
S11 |
p. xi5
|
artikel
|
| 60 |
In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers
|
Datar, I.
|
|
|
|
S11 |
p. xi5
|
artikel
|
| 61 |
introduction
|
|
|
|
|
S11 |
p. xi1
|
artikel
|
| 62 |
Ipilimumab for advanced melanoma in the real world: The Northern Ireland experience
|
Gallagher, P.F.
|
|
|
|
S11 |
p. xi6-xi7
|
artikel
|
| 63 |
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
|
Miller, M.
|
|
|
|
S11 |
p. xi1-xi2
|
artikel
|
| 64 |
KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)
|
Licitra, L.
|
|
|
|
S11 |
p. xi28-xi29
|
artikel
|
| 65 |
Markers of inflammation as prognostic factors for survival in peripheral T-cell lymphoma in Peru
|
Castro, D.
|
|
|
|
S11 |
p. xi13
|
artikel
|
| 66 |
Mechanistic divergence of immune checkpoint inhibition by an ex vivo platform derived from patient tumors where tumor and immune microenvironment is preserved
|
Biswas, M.
|
|
|
|
S11 |
p. xi25
|
artikel
|
| 67 |
miR-4317, a novel tumor suppressor miRNA, alleviates immune-suppressive microenvironment induced by breast cancer
|
Youness, R.A.
|
|
|
|
S11 |
p. xi23
|
artikel
|
| 68 |
Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy
|
Kapp, K.
|
|
|
|
S11 |
p. xi16
|
artikel
|
| 69 |
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer
|
Frenzel, K.
|
|
|
|
S11 |
p. xi29
|
artikel
|
| 70 |
Next steps in access and availability of opioids for the treatment of cancer pain: reaching the tipping point?
|
Cleary, J.
|
|
|
|
S11 |
p. xi60-xi64
|
artikel
|
| 71 |
NK-cell based delivery of anticancer therapeutics
|
Koval, O.
|
|
|
|
S11 |
p. xi20
|
artikel
|
| 72 |
Novel and promising therapeutic approaches for glioblastoma: Blocking CD47-SIRPα axis alone or combined with autophagy depletion
|
Zhang, X.
|
|
|
|
S11 |
p. xi4
|
artikel
|
| 73 |
Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors
|
Grzybowski, M.M.
|
|
|
|
S11 |
p. xi20-xi21
|
artikel
|
| 74 |
Oncolytic adenovirus expressing tumor neoepitopes as a vaccine
|
Sal, M Farrera
|
|
|
|
S11 |
p. xi15-xi16
|
artikel
|
| 75 |
Oncolytic virotherapy using the chimeric rhabdovirus VSV-GP: Tumor-selective induction of cell death and immune-activation
|
Wollmann, G.
|
|
|
|
S11 |
p. xi17
|
artikel
|
| 76 |
Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus
|
McElwaine-Johnn, H.
|
|
|
|
S11 |
p. xi14
|
artikel
|
| 77 |
Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma
|
Cunningham, D.
|
|
|
|
S11 |
p. xi27
|
artikel
|
| 78 |
PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC
|
Wong, D.
|
|
|
|
S11 |
p. xi3
|
artikel
|
| 79 |
Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)
|
Mauti, L.
|
|
|
|
S11 |
p. xi8
|
artikel
|
| 80 |
Peptide-MHC-directed expansion of multifunctional antigen-responsive T cells
|
Rasmussen, V.M.
|
|
|
|
S11 |
p. xi20
|
artikel
|
| 81 |
Peptide vaccination against PD-L1 in multiple myeloma: A phase I trial
|
Jørgensen, N.G.
|
|
|
|
S11 |
p. xi28
|
artikel
|
| 82 |
Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
|
Machiels, J-P
|
|
|
|
S11 |
p. xi28
|
artikel
|
| 83 |
Phase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME)
|
Hong, D.
|
|
|
|
S11 |
p. xi1
|
artikel
|
| 84 |
Plasma levels of interleukin-33 (IL-33) and soluble suppression of tumorigenicity 2 (sST2) as a potential predictive biomarker in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systemic chemotherapy (sCTX)
|
Kieler, M.
|
|
|
|
S11 |
p. xi11-xi12
|
artikel
|
| 85 |
plenary session
|
|
|
|
|
S11 |
p. xi3-xi4
|
artikel
|
| 86 |
plenary session
|
|
|
|
|
S11 |
p. xi1-xi2
|
artikel
|
| 87 |
PRAME, cell migration and invasion of triple negative breast cancer cells
|
Al-Sulaiti, B.
|
|
|
|
S11 |
p. xi26
|
artikel
|
| 88 |
Predictive effect of cytokines in non-small cell lung cancer
|
Huber, R.M.
|
|
|
|
S11 |
p. xi11
|
artikel
|
| 89 |
Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer
|
Dosset, M.
|
|
|
|
S11 |
p. xi8-xi9
|
artikel
|
| 90 |
Presence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma
|
Meynard, G.
|
|
|
|
S11 |
p. xi24
|
artikel
|
| 91 |
Pretherapeutic inflammation status and cytokine profile may predict response to immunotherapy in NSCLC patients
|
Kauffmann-Guerrero, D.
|
|
|
|
S11 |
p. xi12
|
artikel
|
| 92 |
Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
|
Reck, M.
|
|
|
|
S11 |
p. xi31
|
artikel
|
| 93 |
Priming and expansion of neo-antigen specific-T cells thanks to an off-the-shelf cell-based drug product
|
Plumas, J.
|
|
|
|
S11 |
p. xi18-xi19
|
artikel
|
| 94 |
Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich
|
Sanoyan, D Akhoundova
|
|
|
|
S11 |
p. xi7
|
artikel
|
| 95 |
Real world analysis for immune related side effects in 3000 patients
|
Mitrofan, L.
|
|
|
|
S11 |
p. xi7-xi8
|
artikel
|
| 96 |
Replacing lymphodepleting preconditioning with an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin-2 in adoptive cell therapy
|
Santos, J.M.
|
|
|
|
S11 |
p. xi19
|
artikel
|
| 97 |
Selective internal radiation therapy (SIRT) promotes the recruitment of tumor-infiltrating lymphocytes and enhances cytotoxic activity in hepatocellular carcinoma
|
Craciun, L.
|
|
|
|
S11 |
p. xi3
|
artikel
|
| 98 |
Serological assessment of extracellular matrix (ECM) remodeling in relation to clinical response in metastatic melanoma patients treated with ipilimumab
|
Jensen, C.
|
|
|
|
S11 |
p. xi10
|
artikel
|
| 99 |
session A
|
|
|
|
|
S11 |
p. xi5-xi17
|
artikel
|
| 100 |
session A: gastrointestinal tumours
|
|
|
|
|
S11 |
p. xi3-xi23
|
artikel
|
| 101 |
session B
|
|
|
|
|
S11 |
p. xi18-xi25
|
artikel
|
| 102 |
session B: lung cancer
|
|
|
|
|
S11 |
p. xi24-xi36
|
artikel
|
| 103 |
session C
|
|
|
|
|
S11 |
p. xi26-xi38
|
artikel
|
| 104 |
session C: early and advanced breast cancer
|
|
|
|
|
S11 |
p. xi37-xi55
|
artikel
|
| 105 |
session D
|
|
|
|
|
S11 |
p. xi39-xi48
|
artikel
|
| 106 |
session D: miscellanea
|
|
|
|
|
S11 |
p. xi56-xi88
|
artikel
|
| 107 |
session E
|
|
|
|
|
S11 |
p. xi49-xi55
|
artikel
|
| 108 |
session E: nursing
|
|
|
|
|
S11 |
p. xi89-xi91
|
artikel
|
| 109 |
session F
|
|
|
|
|
S11 |
p. xi56-xi59
|
artikel
|
| 110 |
session G
|
|
|
|
|
S11 |
p. xi60-xi64
|
artikel
|
| 111 |
session H
|
|
|
|
|
S11 |
p. xi65-xi74
|
artikel
|
| 112 |
session L
|
|
|
|
|
S11 |
p. xi75-xi83
|
artikel
|
| 113 |
session M
|
|
|
|
|
S11 |
p. xi84-xi87
|
artikel
|
| 114 |
STAT3 inhibition reduces self-renewal in gastric cancer and promotes immune activation
|
Ebrahimi, M.
|
|
|
|
S11 |
p. xi22
|
artikel
|
| 115 |
Table of Contents
|
|
|
|
|
S11 |
p. iv
|
artikel
|
| 116 |
Table of Contents
|
|
|
|
|
S11 |
p. v
|
artikel
|
| 117 |
Table of Contents
|
|
|
|
|
S11 |
p. i
|
artikel
|
| 118 |
Table of Contents
|
|
|
|
|
S11 |
p. iv
|
artikel
|
| 119 |
Targeting lymphoma with CD37CAR: A pre-clinical study
|
Walchli, S.
|
|
|
|
S11 |
p. xi5
|
artikel
|
| 120 |
T cell recognition of breast cancer antigens
|
Ramskov, S.
|
|
|
|
S11 |
p. xi19
|
artikel
|
| 121 |
T cell responses in patients with melanoma resistant to multiple immunotherapies
|
Andersen, R.
|
|
|
|
S11 |
p. xi4
|
artikel
|
| 122 |
T-cell therapy: Enabling oncolytic adenoviruses for the treatment of melanoma
|
Santos, J.M.
|
|
|
|
S11 |
p. xi16
|
artikel
|
| 123 |
T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients
|
Borch, T.H.
|
|
|
|
S11 |
p. xi29
|
artikel
|
| 124 |
TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma
|
Mariathasan, S.
|
|
|
|
S11 |
p. xi30
|
artikel
|
| 125 |
Thank you and acknowledgement
|
|
|
|
|
S11 |
p. xi5
|
artikel
|
| 126 |
The association of the level of serum of interleukin-10 and its polymorphism gene with the risk and the prognosis for colorectal cancer in Tunisia
|
Braham, J.A.
|
|
|
|
S11 |
p. xi13
|
artikel
|
| 127 |
The Board of Directors for the years 2005-2007 includes:
|
|
|
|
|
S11 |
p. xi2
|
artikel
|
| 128 |
The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology
|
Cherny, N.I.
|
|
|
|
S11 |
p. xi7-xi13
|
artikel
|
| 129 |
The immune modulation role of low dosage of cyclosporin-A (ldCSA) in the antitumor response of CD8+ T lymphocytes (CD8+Tcells) and the implication of neuropilin-1 (Nrp1)
|
Flores, C.
|
|
|
|
S11 |
p. xi21
|
artikel
|
| 130 |
Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
|
Smalley, M.
|
|
|
|
S11 |
p. xi9
|
artikel
|
| 131 |
The role of IL10, IL6 and TNFα as potential prognostic markers in breast cancer in Tunisia
|
Braham, J.A.
|
|
|
|
S11 |
p. xi13
|
artikel
|
| 132 |
Title Page
|
|
|
|
|
S11 |
p. ii
|
artikel
|
| 133 |
Translational Research Index
|
|
|
|
|
S11 |
p. xi33
|
artikel
|
| 134 |
Tumor-infiltrating lymphocytes, tumor-associated macrophages and HLA class 1 expression in breast cancer patients treated with neoadjuvant chemotherapy with or without zoledronic acid: A sub study of the NEOZOTAC trial
|
de Groot, A.F.
|
|
|
|
S11 |
p. xi9
|
artikel
|
| 135 |
XIST and TSIX: Novel cancer-immune biomarkers showing differential expression in tumor, PBMCs, serum, nipple discharge and lymph nodes of PD-L1 overexpressing BC patients
|
Atef, E.
|
|
|
|
S11 |
p. xi13
|
artikel
|
Tijdschrift beschrijving